STRUCTURED LITERATURE REVIEW OF THE PREVALENCE OF MICROSATELLITE INSTABILITY HIGH (MSI-H) AND DEFICIENT MISMATCH REPAIR (DMMR) AMONG SOLID TUMORS

被引：0
|
作者：
Lorenzi, M. [1 ]
Amonkar, M. [1 ]
Zhang, J. [1 ]
Mehta, S. [1 ]
Liaw, K. [2 ]
机构：
[1] Precis Xtract, Oakland, CA USA
[2] Merck & Co Inc, N Wales, PA USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.135
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN53
引用
收藏
页码：S22 / S23
页数：3
相关论文
共 50 条
  • [21] Impact of RAS mutations on immunologic characteristics of the tumor microenvironment (TME) in patients with microsatellite instability-high (MSI-H) or mismatch-repair-deficient (dMMR) colorectal cancer (CRC).
    Salem, Mohamed E.
    Andre, Thierry
    El-Refai, Sherif Mohamed
    Kopetz, Scott
    Tabernero, Josep
    Sinicrope, Frank A.
    Tie, Jeanne
    George, Thomas J.
    VanCutsem, Eric
    Mauer, Elizabeth
    Lonardi, Sara
    Overman, Michael J.
    Foureau, David
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [22] The efficacy of pembrolizumab in patients with high-frequency microsatellite instability (MSI-H) solid tumors
    Sugimoto, Naotoshi
    Hasegawa, Akiko
    Takada, Ryoji
    Abe, Yutaro
    Kai, Yugo
    Fukutake, Nobuyasu
    Ikezawa, Kenji
    Yamamoto, Sachiko
    Watanabe, Masahiro
    Hisa, Tsuyoshi
    Oota, Yukinobu
    Kuno, Ikumi
    Otsuka, Tomoyuki
    Nishio, Minako
    Kudo, Toshihiro
    Fujisawa, Fumie
    Yagi, Toshinari
    Ohkawa, Kazuyoshi
    Kamiura, Shoji
    Imamura, Fumio
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S302 - S302
  • [23] Efficacy of HX008 in high microsatellite instability/mismatch repair-defificient (MSI-H/dMMR) solid tumors: Results from a multicenter phase II open-label study.
    Huang, Jing
    Song, Yan
    Luo, Suxia
    Yin, Xianli
    Li, Enxiao
    Wang, Hui
    He, Yifu
    Liu, Zhihui
    Fan, Qingxia
    Liang, Xinjun
    Shu, Yongqian
    Liu, Yunpeng
    Xu, Nong
    Zhang, Shu
    Zhuang, Zhixiang
    Zhang, Jingdong
    Kou, Xiaoge
    Wang, Fen
    Zhu, Xiaodong
    Li, Shengmian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors
    Ludford, Kaysia
    Ho, Won Jin
    Thomas, Jane V.
    Raghav, Kanwal P. S.
    Murphy, Mariela Blum
    Fleming, Nicole D.
    Lee, Michael S.
    Smaglo, Brandon G.
    You, Y. Nancy
    Tillman, Matthew M.
    Kamiya-Matsuoka, Carlos
    Thirumurthi, Selvi
    Messick, Craig
    Johnson, Benny
    Vilar, Eduardo
    Dasari, Arvind
    Shin, Sarah
    Hernandez, Alexei
    Yuan, Xuan
    Yang, Hongqui
    Foo, Wai Chin
    Qiao, Wei
    Maru, Dipen
    Kopetz, Scott
    Overman, Michael J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (12) : 2181 - +
  • [25] Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors
    Li, Jian
    Xu, Ye
    Zang, Aimin
    Gao, Yunong
    Gao, Quanli
    Zhang, Yanqiao
    Wang, Dong
    Xu, Jianming
    Yuan, Ying
    Jiang, Haiping
    Ying, Jieer
    Shi, Chunmei
    Deng, Yanhong
    Wang, Jing
    Liu, Tianshu
    Huang, Yi
    Xu, Yaling
    Wang, Yidi
    Fei, Cong
    Shen, Lin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [26] Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): The GARNET study.
    Oaknin, Ana
    Pothuri, Bhavana
    Gilbert, Lucy
    Sabatier, Renaud
    Ghamande, Sharad A.
    Gravina, Adriano
    Calvo, Emiliano
    Banerjee, Susana N.
    Miller, Rowan
    Pikiel, Joanna
    Mirza, Mansoor Raza
    Duan, Tao
    Zildjian, Sybil
    Zografos, Eleftherios
    Veneris, Jennifer Taylor
    Tinker, Anna
    Powell, Matthew A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] The efficacy and safety of neoadjuvant immunotherapy in patients with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) localized and oligometastatic colon cancer: Data from the real world.
    Chakrabarti, Sakti
    Parish, Marie
    Peterson, Carrie
    Ludwig, Kirk A.
    Sriram, Deepika
    Ruggeri, Antony
    Tolay, Sameer
    Selfridge, Jennifer Eva
    Bajor, David L.
    Mohamed, Amr
    Mahipal, Amit
    Shreenivas, Aditya V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 105 - 105
  • [28] Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H)
    Berton-Rigaud, D.
    Pautier, P.
    Lorusso, D.
    Gennigens, C.
    Gladieff, L.
    Kryzhanivska, A.
    Bowman, J.
    Tian, C.
    Cornfeld, M.
    Van Gorp, T.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S517 - S517
  • [29] Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors.
    Li, Jian
    Xu, Ye
    Zang, Aimin
    Gao, Yunong
    Gao, Quanli
    Zhang, Yanqiao
    Wang, Dong
    Xu, Jianming
    Yuan, Ying
    Jiang, Haiping
    Ying, Jieer
    Shi, Chunmei
    Deng, Yanhong
    Wang, Jing
    Liu, Tianshu
    Huang, Yi
    Xu, Yaling
    Wang, Yidi
    Fei, Cong
    Shen, Lin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) stage IV colorectal cancer (CRC)
    Andre, Thierry
    Sposetti, Caterina
    Gumus, Mahmut
    Ahn, Joong Bae
    Wyrwicz, Lucjan
    Kwiatkowski, Mariusz
    Kim, Jong Gwang
    Yalcin, Suayib
    Sendur, Mehmet A. N.
    Odeleye-Ajakaye, Amos
    Leconte, Pierre
    Fogelman, David R.
    Kim, Tae Won
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345